Drugs that contain Pacritinib Citrate

1. Vonjo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(4 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-397) Feb 28, 2029
New Chemical Entity Exclusivity(NCE) Feb 28, 2027

NCE-1 date: 28 February, 2026

Market Authorisation Date: 28 February, 2022

Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)


More Information on Dosage

VONJO family patents

Family Patents